Pulmonology Xagena
Results of a clinical study showed that Xolair ( Omalizumab ) halved the rate of severe asthma exacerbations and reduced the rate of hospital emergency visits by 44% in patients with inadequately cont ...
In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium ( Spiriva ) Respimat, a once-daily long-acting anticholinergic ...
Omalizumab ( Xolair ) has been recommended as an add-on option for the treatment of patients with moderate-severe allergic asthma uncontrolled with high doses of corticoid inhaled therapy. In addition ...